Before the U.S. cash open, the single most important fact for traders: breadth is mixed and macro is neutral — the opening setup shows VIX at 15.5 with the 10-year near 4.96%, and cannabis names are rangebound, so position sizing should be smaller and catalyst-linked. The broader market context from the opening setup brief cites VIX 15.5 and 10Y 4.96% while the S&P was down 0.4% and the dollar index up 0.6%, a backdrop that the brief says leaves no macro edge for a sustained sector move; follow-through for TLRY or CRBP will depend more on company catalysts than a macro push, with the opening note specifically pointing to neutral macro and rangebound action across the 326-ticker cannabis universe. On deals and capital markets, there is nothing new in today’s briefs about fresh M&A or major equity raises — the prior close brief reiterates that analyst upside exists but timing is uncertain — the session close called for selective, catalyst-anchored positioning and again noted analyst consensus tilting bullish with 44 Buys, 6 Holds and 7 Sells, a tally that underpins why capital markets activity may remain selective for names like TLRY or CRBP until macro clarity arrives. From an analyst and market-structure angle, use the consensus and short-interest signals to frame risk: both the opening and prior-close briefs show analyst coverage skewed to the buy side — 44 Buys — while the shared facts package points to concentrated short interest and elevated days-to-cover in IIPR at 11.2 days-to-cover, which the opening setup also flagged; that asymmetric placement of shorts versus buy-side conviction is a reason to monitor any squeeze signals in IIPR and to respect stop discipline on long positions. Pre-market movers on U.S. tape are visible in the movers package: Medical Marijuana Inc (MJNA) is up 100.0% on U.S. tape, Cannara Biotech (CANN) has rallied roughly 26.4% on Canada & OTC tape, and Pharmacielo Ltd. (PCLO) is up 10.0% on Canada & OTC tape — the facts package lists these percentage moves and volumes (MJNA volume 1,035,274; CANN volume 2,430; PCLO volume 22,015), so expect headline-driven, short-term activity in these tickers rather than sustained sector leadership. On downside movers, Springbig Holdings (INSU) slid 47.37% on the U.S. tape and Skye Bioscience (SKYE) fell 19.43%, both recorded in the shared daily facts package; those falls reflect idiosyncratic negative updates or liquidity events and underscore the call in the prior close brief to avoid broad-beta adds — focus instead on names with clear catalysts and adequate liquidity. Midday commentary earlier in the session suggested constructive breadth — the midday brief showed an expansion to 27 advancing versus 6 declining across the 326-ticker universe (82% up) with the S&P at +0.3% and VIX at 16.9 — but that improvement is explicitly conditional in the brief: trim conviction if breadth deteriorates before a macro regime shift, and treat momentum names as tactical opportunities, not strategic reallocations; CRBP is called out repeatedly for implied upside (widest implied upside to $34.02) and should be on watchlists because the briefs cite that figure consistently. For traders, the single thing to watch for the rest of the day is whether breadth sustains the midday expansion — if advancing counts remain elevated versus the 16/17 split seen at prior close, momentum names like CRBP and TLRY could extend; if breadth collapses, defensive trimming is advised. Read the full US brief at https://www.cannabisinvestornews.co/brief.html?region=us.
Read the full US brief for 2026-09-17.
